Boehringer Ingelheim's Trajenta ranked no.1. among the outpatient prescription cost of DPP-4 family drugs

According to the outpatient prescription cost of DPP-4 family drugs in the first half of 2014 based on Ubist data, it was identified that Boehringer Ingelheim's Trajenta ranked no.1. Trajenta used sales capacity of Yuhan Corporation as a steppingstone and showed 13.5% growth from 22.1 billion won in the first half of 2013 to 25.1 billion won in the first half of 2014.

On the other hand, Januvi...